Rocket Lab's Neutron Debut Pushed to 2027 After Fuel-Tank Defect, and the Street Is Repricing the Wait
Published on 10/18/2026 at 12:50 | Editorial boerse-global.de
Rocket Lab shareholders had no time to catch their breath on Friday. The stock shed 8.2% to close at EUR 45.25, capping a rough stretch set in motion two days earlier, when the company disclosed a manufacturing problem with the forward dome of Neutron's first-stage fuel tank and pushed the rocket's maiden flight into 2027.
The original target had been the fourth quarter of 2026. Instead, the composite-structure flaw — air pockets trapped in the carbon-fiber forward dome — has forced rework that management says is finished, alongside process improvements meant to prevent a repeat. The market, though, is focused on the calendar. Reuters and the Los Angeles Times both reported that the slip was the main driver of the selloff.
Two Days, Four Targets
The analyst response came fast and in force. Clear Street moved first on Thursday, cutting its price target to $105 from $129 while keeping a Buy rating. Citizens JMP followed a day later with a far deeper trim, slashing its fair value to $90 from $130 but holding firm on Outperform.
Goldman Sachs analyst Noah Poponak stayed at Hold and lowered his target to $67 from $75, modeling Neutron's first launch for the second quarter of 2027 and flagging higher spending and a bigger cash burn over the coming quarters. KeyBanc's Michael Leshock kept his Buy rating but took his target down to $100 from $135, citing both the revised Neutron schedule and valuation discounts across high-growth space stocks. Other observers followed, with some targets landing as low as $90.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The pattern is hard to miss: nearly every firm trimmed its number, and almost none touched its rating. That combination — smaller targets, intact conviction — suggests the analysts are not running for the exits. They are simply marking down the wait.
What the Delay Actually Costs
The financial arithmetic behind those cuts is straightforward. Neutron is Rocket Lab's ticket into heavier payload classes, and a later first flight pushes back the revenue that follows it. Proceeds from subsequent missions in fiscal 2027 and 2028 are now expected to arrive later than previously modeled, and the added outlays tied to the rework put a dent in the cash position.
At 66% below its 52-week high, the stock is already carrying a hefty risk discount. Whether that discount is wide enough is the question dividing the market from the research desks.
The Case for Patience
Building a brand-new rocket class rarely goes to plan, and catching a composite defect on the ground is vastly preferable to discovering it in flight. Addressing the tank issue early is, operationally, the only defensible call — even if the schedule pays for it.
Still, investors should not gloss over what lies ahead. Until the new 2027 window arrives, the shares remain exposed to any further operational stumble, and the era of easy advance praise is over. What matters now is flawless industrial execution. On the current valuation, the long-term opportunity may well outweigh the near-term pain — but this is not a position for the faint of heart.
Ad
Rocket Lab Stock: New Analysis - 18 October
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
